Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Chief Commercial Officer | July 09, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date July 09, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 290,623 |
Reported balance
After 2026-07-09 transaction · row 1
1 source rowRow 1 · 2026-07-09 · Sale · Disposed 12,606 · Balance 290,623 F1: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 9, 2026 23:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 12,606 | $6.96 | $87,784.40 |
DisclosureSEC source: 0001493152-26-032740 · ownership.xml · nonDerivative · entry 1 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,623 F1 · kind: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | OtherCommon Stock | 222 | $5.67 | $1,258.74 |
DisclosureSEC source: 0001493152-26-029092 · ownership.xml · nonDerivative · entry 1 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,229 F1 · kind: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 5,450 | $5.30 | $28,907.89 |
DisclosureSEC source: 0001493152-26-028021 · ownership.xml · nonDerivative · entry 2 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,451 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 4,170 | $5.43 | $22,641.02 |
DisclosureSEC source: 0001493152-26-028021 · ownership.xml · nonDerivative · entry 1 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,901 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 11, 2026 Filed May 11, 2026 22:36 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 5,548 | $5.96 | $33,073.29 |
DisclosureSEC source: 0001493152-26-022332 · ownership.xml · nonDerivative · entry 1 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,071 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.00 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 12,610 | $5.29 | $66,657.72 |
DisclosureSEC source: 0001493152-26-003611 · ownership.xml · nonDerivative · entry 2 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,619 F2 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.28 to $5.35 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 20, 2026 Filed Jan 26, 2026 21:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 76,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003611 · ownership.xml · nonDerivative · entry 1 Vasanthavada Madhav · CIK 0002106295 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,229 F1 · shares: The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.